Report
EUR 13.08 For Business Accounts Only

Increased risk weighs on JINXIN FERTILITY GROUP, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of JINXIN FERTILITY GROUP (HK), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date January 21, 2022, the closing price was HKD 8.71 and its target price was estimated at HKD 6.53.
Underlying
Jinxin Fertility Group Ltd.

Jinxin Fertility Group Ltd. Jinxin Fertility Group Limited is a China-based company principally engaged in the provision of assisted reproductive services (ARS). The Company operates its business through three segments. The ARS segment primarily provides its patients with two treatment solutions: artificial insemination (AI) and in vitro fertilization (IVF) technology. The Management Services segment provides management services to Jinjiang IVF Center and Jinxin Fertility Center. The Ancillary Medical Services segment mainly provides medical services in the areas of gynecology, urology and internal medicine through Shenzhen Zhongshan Hospital. The Company mainly operates its business in China and the Unites.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch